Kibow renews exclusive worldwide veterinary licensing and marketing agreement

Kibow Biotech, Inc. today announced that it has renewed its exclusive worldwide licensing and marketing agreement with the current licensing partner specializing in animal health. The agreement concerns "Azodyl™," a patented, 100% natural, probiotic dietary supplement indicated for the reduction of azotemia in dogs and cats with moderate to severe renal failure. Developed by Kibow, Azodyl™ has been successfully marketed and sold mainly in USA and Canada since July 2006.

Kibow intends to utilize a major portion of the $2.4 million funding secured for testing a similar, patented, probiotic dietary supplement intended for human consumption. This flagship product, known as "Kibow Biotics™," is targeted towards kidney health and helps improve the quality of life in chronic kidney failure (CKF) patients who also adhere to their routine standardized care of treatment for their pre-existing medical conditions.

Kibow's human clinical trials, involving dialysis and pre-dialysis patients, have already been initiated at Thomas Jefferson University, Philadelphia, PA and at Downstate Medical Center/Kings County Hospitals, State University of New York (SUNY), Brooklyn, NY. Another trial, to be conducted at Mayo clinic, Rochester, MN is soon to begin.

Comments

  1. Vilma Dela Cruz Vilma Dela Cruz Philippines says:

    My father has chronic renal insufficiency, his creatinine is 278 and BUA of 18, also his potassum is not eliminated properly . I am interested to try your product. It may delay the proposed dialysis treatment as oredered by his physician.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
COVID-19 virus can breach blood-retinal barrier, study finds